前沿速览025期| CAR-T治B淋 前沿览新知
01
在第三线或更晚线治疗中，比较epcoritamab与化学免疫治疗、含polatuzumab的方案、含tafasitamab的方案或CAR-T细胞疗法治疗复发/难治性大B细胞淋巴瘤的结局
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
第一作者：Rosenthal A
J Hematol Oncol (IF=29.5). 2024 Aug 16;17(1):69.
全文网址：https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01594-x
02
滤泡性淋巴瘤的治疗：研究进展与未来展望
Current and future therapies for follicular lymphoma
第一作者：Zinzani PL
Exp Hematol Oncol (IF=9.4). 2024 Aug 22;13(1):87.
全文网址：https://ehoonline.biomedcentral.com/articles/10.1186/s40164-024-00551-1
03
接受CD19 CAR-T细胞疗法的大B细胞淋巴瘤患者的预后的生物标志物
Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma
第一作者：Gong IY
Hemasphere (IF=7.6). 2024 Aug 22;8(8):e130.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339649/
04
局部放疗可通过增强抗原交叉呈递和T细胞浸润来提高全身CAR-T细胞的疗效
Local Radiation Enhances Systemic CAR T Cell Efficacy by Augmenting Antigen Cross-Presentation and T-cell Infiltration
第一作者：Kostopoulos N
Blood Adv (IF=7.4). 2024 Aug 30:bloodadvances.2024012599.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024012599/517646/Local-Radiation-Enhances-Systemic-CAR-T-Cell
05
在接受CAR-T细胞治疗前后使用tafasitamab联合来那度胺治疗的大B细胞淋巴瘤患者的疗效
Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells
第一作者：Camus V
Blood Adv (IF=7.4). 2024 Aug 20:bloodadvances.2024013726.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013726/517474/Outcome-of-large-B-cell-lymphoma-patients-treated
06
一种敏感且可靠的综合ddPCR策略，可用于临床实践中监测CAR-T细胞动力学
A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications
第一作者：Wiedemann G
Int J Mol Sci (IF=4.9). 2024 Aug 6;25(16):8556.
全文网址：https://www.mdpi.com/1422-0067/25/16/8556
07
Brexucabtagene autoleucel治疗后产生的迟发性复发性神经毒性，与脑脊液中CAR-T细胞数量高相关
Late-onset relapsing neurotoxicity after Brexucabtagene autoleucel associated with high chimeric antigen receptor T cells in cerebrospinal fluid
第一作者：De Philippis C
Cytotherapy (IF=3.7). 2024 Aug 3:S1465-3249(24)00822-3.
全文网址：https://www.isct-cytotherapy.org/article/S1465-3249(24)00822-3/abstract
08
在接受Axicabtagene Ciloleucel治疗的复发/难治性大B细胞淋巴瘤患者中预防性使用托珠单抗
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma
第一作者：Locke FL
Transplant Cell Ther (IF=3.6). 2024 Aug 24:S2666-6367(24)00619-5.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S2666-6367(24)00619-5
09
CD19 CAR-T细胞治疗B细胞恶性肿瘤：一项系统评价和荟萃分析，重点关注CAR结构域、制备条件、细胞产品、细胞剂量、患者年龄和肿瘤类型的临床影响
CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient's age, and tumor types
第一作者：Montagna E
BMC Cancer (IF=3.4). 2024 Aug 22;24(1):1037.
全文网址：https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12651-6
10
在套细胞淋巴瘤患者中，接受苯达莫司汀治疗后的淋巴细胞恢复状况：回顾性分析结果及CAR-T时代预后影响
Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era
第一作者：Donzelli L
Ann Hematol (IF=3.0). 2024 Aug 30.
全文网址：https://link.springer.com/article/10.1007/s00277-024-05962-y
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.9-2 valid until 2026.9
供稿与审核：临床开发与医学部